Legislation Search

H.R. 4392: Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025

This bill, titled the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025, aims to enhance the detection and treatment of uterine fibroids, which are non-cancerous growths in the uterus. Here are the main components of the bill:

Research on Uterine Fibroids

The bill mandates that the Secretary of Health and Human Services must:

Conduct or support research focused on improving the early detection and intervention for uterine fibroids.
Develop evidence-based strategies to enhance early detection in healthcare settings.

The Secretary is required to finalize these strategies as quickly as possible for implementation by grant recipients.

Grants for States

The bill allows the Secretary to award grants to states to fund programs aimed at:

Increasing the early detection and intervention of uterine fibroids.
Developing and implementing awareness and educational campaigns for uterine fibroids.

Use of Grant Funds

States that receive grants can use the funds for various activities, including:

Screening procedures and advanced gynecological imaging.
Providing patient navigation services to assist individuals in accessing care.
Implementing evidence-based strategies for early detection.
Facilitating better access to healthcare services.

Priority for Vulnerable Populations

When awarding grants, priority will be given to states with programs designed for areas that have socially vulnerable populations that are at a higher risk of developing uterine fibroids.

Research Initiatives

The Secretary also has the authority to award additional grants for research, which may include:

Studies on disparities in pain management and surgical treatments for uterine fibroids.
Research on Asherman’s Syndrome and other intrauterine conditions as identified by the Secretary.

Reporting Requirements

The bill establishes reporting obligations for the Secretary of Health and Human Services. These include:

Submitting a report to Congress every two years summarizing the results of the funded programs.
Providing updates on research developments related to uterine fibroids and relevant conditions, also every two years.